mRNA-Encoded Gene Editing Accelerates Clinical Translation

In a move to accelerate the translation of gene editing research into clinical applications, Danaher companies Integrated DNA Technologies (IDT) and Aldevron have co-developed research-grade S.p. Cas9 mRNA in wild type and SpyFi high-fidelity formats. This new offering is designed to provide researchers and therapeutic developers with high-quality Cas9 mRNA for CRISPR-based genome editing workflows, thereby facilitating efficient editing, reduced off-target risk, and greater continuity as programs advance.

According to Christopher Vakulskas, Senior Director, Applied Science and Molecular Design at IDT, gene editing researchers are under pressure to move faster without compromising performance, reproducibility, or flexibility. To address this challenge, IDT and Aldevron have leveraged their combined expertise in CRISPR protein engineering and mRNA manufacturing to develop an optimized Cas9 mRNA offering.

The new offering is designed to support high on-target editing efficiency across multiple cell types, including T cells, iPSCs, and immortalized cells, while the SpyFi high-fidelity version helps reduce off-target editing risk. The mRNA formats are compatible with delivery via electroporation, cationic lipids, and lipid nanoparticles (LNP), providing customers with flexibility to select the approach that best fits their application.

Notably, the Cas9 mRNA is enzymatically capped, offering customers a high-performing alternative to certain proprietary capping technologies. By reducing licensing burden and simplifying access, the offering helps researchers focus on advancing their science rather than managing licensing complexity.

This launch marks the first in a suite of co-developed offerings from IDT and Aldevron, with base and prime editors slated for later this year. The companies are building on their rich history of working together to provide customers with critical tools and manufacturing support for genomic medicine workflows, and are now expanding their partnership to equip customers with a new mRNA modality option for Cas9-based gene editing.

The solution combines IDT's guide RNA design and analysis expertise with Aldevron's mRNA manufacturing capabilities, resulting in a streamlined experience for customers advancing Cas9-based gene editing programs from early research through CGMP manufacturing.

The introduction of this new offering is a testament to the power of connected expertise within the Danaher companies. By leveraging their combined strengths in CRISPR protein engineering and mRNA manufacturing, IDT and Aldevron are empowering researchers to accelerate the translation of gene editing research into clinical applications, and ultimately, to improve human health.

In the context of gene editing advances toward clinically relevant ex vivo and in vivo applications, the need for CRISPR mRNA reagents that deliver reproducible editing performance, reduce technical risk, support emerging delivery approaches, and fit into programs that may ultimately need to scale is increasingly pressing. IDT and Aldevron's co-developed Cas9 mRNA directly addresses these challenges through optimized constructs manufactured in consistent research-grade formats, with a path to scaled CGMP-manufactured versions as programs progress.

In conclusion, the launch of research-grade S.p. Cas9 mRNA in wild type and SpyFi high-fidelity formats by IDT and Aldevron is a significant development in the field of gene editing. By providing researchers with high-quality Cas9 mRNA, the companies are empowering the advancement of gene editing research and its translation into clinical applications, ultimately paving the way for improved human health and disease treatment.